Physician profile
Celine L Rivera
NPI 1407052772
$11,493.96
in general payments reported to CMS, 2019-2025
60 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $1,813 · 2021: $3,071 · 2022: $1,118 · 2023: $1,648 · 2024: $1,831 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,793.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,233.82 | 2019-2025 | Repatha, Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $750.00 | 2021 | |
| Astellas Pharma US INC | $731.92 | 2019-2025 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $713.86 | 2020-2025 | Injectafer, Enhertu |
| Astrazeneca Pharmaceuticals LP | $702.87 | 2019-2025 | Enhertu, Farxiga, Airsupra |
| Pfizer INC. | $653.76 | 2020-2024 | |
| Lilly USA, LLC | $620.00 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $589.55 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $517.90 | 2019-2025 | Vraylar |
| Novartis Pharmaceuticals Corporation | $503.91 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $501.53 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $468.18 | 2019-2022 | |
| Glaxosmithkline, LLC. | $419.21 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $351.88 | 2020-2025 | Spravato |
| Merck Sharp & Dohme LLC | $344.40 | 2020-2024 | Gardasil, Capvaxive, Gardasil 9 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celine Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.